Accera to sponsor National Memory Screening Day of Alzheimer's Foundation of America

NewsGuard 100/100 Score

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today that it is a silver sponsor of the Alzheimer's Foundation of America's (AFA) National Memory Screening Day (NMSD) on November 13, 2012 during National Alzheimer's Disease Awareness Month.

"We're pleased to continue our relationship with the Alzheimer's Foundation," said Holger Kunze, president and CEO of Accera.  "Our company strongly advocates for doing everything possible that can benefit Alzheimer's patients and their caregivers and find the Alzheimer's Foundation's position on comprehensive care to be in direct alliance with our approach."

Accera has developed and sells Axona®, a specially formulated, prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate AD.  It is the first proprietary commercialized AD therapy that addresses the well-recognized physiological hallmark of the brain's inability to optimally metabolize glucose (hypometabolism) by providing an alternative energy source for brain cells.

Eric J. Hall, AFA's president and CEO, stated, "The Alzheimer's Foundation of America is delighted to have the continued support of Accera as a sponsor of National Memory Screening Day.  Its support underscores the company's recognition of the importance of proper diagnosis and its desire to help us fulfill our mission of improving quality of life for people with Alzheimer's disease and their families."  NMSD, an annual initiative initiated by AFA in 2003, provides free, confidential memory screenings to individuals concerned about memory loss or who want to check their memory now and for future comparison with the objective of early detection and intervention.  Qualified healthcare professionals offer the face-to-face screenings and distribute educational materials about memory concerns and successful aging in communities across the nation.  The screening results do not represent a diagnosis, but can indicate whether someone with below-normal results or with concerns should follow up with a physician. 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Quantum biology's new frontier: Tryptophan networks and brain disease defense